Statements (21)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
gptkb:drug |
| gptkbp:CASNumber |
1072958-37-2
|
| gptkbp:clinicalTrialPhase |
Phase II
|
| gptkbp:developedBy |
gptkb:Vertex_Pharmaceuticals
rheumatoid arthritis |
| gptkbp:hasMolecularFormula |
C22H24N6O2S
|
| gptkbp:hasSMILES |
CC1=C(N=C2C=CC=CC2=C1C#N)NC(=O)C3=CC=CC=C3S(=O)(=O)N4CCN(CC4)C
|
| gptkbp:hasUNII |
6Q1K1V0A6F
|
| https://www.w3.org/2000/01/rdf-schema#label |
decernotinib
|
| gptkbp:IUPACName |
N-(3-cyano-4-methyl-1H-indol-7-yl)-3-(4-methylpiperazin-1-yl)sulfonylbenzamide
|
| gptkbp:mechanismOfAction |
Janus kinase 3 inhibitor
|
| gptkbp:molecularWeight |
420.53 g/mol
|
| gptkbp:PubChem_CID |
gptkb:CHEMBL2105727
46216347 |
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:synonym |
VRT-752271
VX-509 |
| gptkbp:bfsParent |
gptkb:Janus_kinases
gptkb:JAK3_gene |
| gptkbp:bfsLayer |
8
|